# Evidence Summary Boswellia and its most important oncology constituent, **AKBA**, have accumulated substantial preclinical evidence across multiple tumour types, with early but meaningful human data in neuro-oncology and breast cancer. ### Research Overview 1. Broad preclinical evidence across colorectal, breast, pancreatic, prostate, lung, glioblastoma, ovarian, and haematologic cancers 2. Randomised clinical data showing Boswellia can reduce radiation-induced cerebral oedema in brain tumour patients 3. Early human window-of-opportunity data in breast cancer showing reduced tumour proliferation markers 4. Orthotopic animal-model data in pancreatic, colorectal, and prostate cancer showing genuine tumour suppression 5. Emerging evidence for treatment-resistance reversal in docetaxel-resistant, cisplatin-sensitive, and radioresistant settings 6. Large Phase III active-treatment oncology data remains limited ### Clinical Application Status **Approved status:** Not approved as a cancer treatment; sold as a supplement or nutraceutical and used in standardised preparations such as H15 Boswelan. **Clinical use:** Used in integrative oncology for anti-inflammatory support, cerebral oedema reduction, treatment-support discussion, and mechanism-based adjunctive use. **Evidence strength:** Strong for cerebral-oedema reduction, strong preclinical overall, and early but meaningful human cancer-tissue data. ### Key Advantages 1. **Multi-pathway action** — simultaneously affects cell cycle, apoptosis, NF-κB, PI3K/Akt, EGFR-related signalling, metastasis, angiogenesis, and epigenetic regulation 2. **Radiation protection plus radiosensitisation** — a clinically important dual profile 3. **Resistance-modifying potential** — especially in docetaxel-resistant prostate and cisplatin-relevant NSCLC contexts 4. **Neuro-oncology relevance** — strong practical value in brain tumour and cerebral-oedema discussions 5. **Generally favourable tolerability** — good safety record across inflammatory and early oncology settings ### Key Considerations 1. **Bioavailability is the main limitation** — formulation and food timing matter 2. **AKBA content matters** — total boswellic acids alone is not enough for oncology-oriented interpretation 3. **CYP interactions matter** — especially with CYP1A2, 2C9, 2C19, 2D6, and 3A4 substrates 4. **Treatment timing still needs review** — especially around chemotherapy and radiotherapy 5. **Human oncology data remains early-stage outside oedema support** ### Bottom line Boswellia is one of the more biologically compelling natural adjuncts for patients dealing with inflammatory burden, radiotherapy-related complications, or treatment-resistance questions. It is not a replacement for standard care, but it is a meaningful adjunctive topic with unusually practical relevance in brain tumour settings. ### Key References Anti-cancer properties of boswellic acids: mechanism of action as an anti-cancerous agent\ The anti-proliferative effects of a frankincense extract in a window of opportunity Phase Ia clinical trial for patients with breast cancer\ An Update on Pharmacological Potential of Boswellic Acids in Cancer\ ### Jump to another Boswellia page **Core pages** * [Boswellia in Oncology Overview](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-in-oncology-overview.md) * [Evidence Summary](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/evidence-summary.md) * [Anticancer Mechanisms](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/anticancer-mechanisms.md) * [Boswellia Evidence by Cancer Type](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type.md) **Mechanism deep dives** * [Redox Dual Action](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/redox-dual-action.md) * [NRF2 Impact](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/nrf2-impact.md) * [Ferroptosis Findings](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/ferroptosis-findings.md) * [Immune Effects](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/immune-effects.md) **Practical pages** * [Pharmacokinetics & Metabolism](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/pharmacokinetics-and-metabolism.md) * [Safety & Interactions](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/safety-and-interactions.md) * [Synergistic Combinations](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/synergistic-combinations.md) * [Hydroxychloroquine + Boswellia](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/hydroxychloroquine-+-boswellia.md) * [Dosing & Timing](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/dosing-and-timing.md) * [Sourcing Quality Boswellia](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/sourcing-quality-boswellia.md) **Cancer-type pages** * [Glioblastoma & Brain Tumours](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/glioblastoma-and-brain-tumours.md) * [Breast Cancer](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/breast-cancer.md) * [Colorectal Cancer](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/colorectal-cancer.md) * [Pancreatic Cancer](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/pancreatic-cancer.md) * [Prostate Cancer](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/prostate-cancer.md) * [Non-Small Cell Lung Cancer](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/non-small-cell-lung-cancer.md) * [Ovarian Cancer](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/ovarian-cancer.md) * [Other Cancer Types](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/other-cancer-types.md) {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/evidence-summary.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.